Antithrombotic therapy.
Coronary heart disease is the leading cause of death in the US and the industrialized world. Ever since DeWood in 1980 demonstrated that a thrombus was the primary event leading to acute myocardial infarction and that they may subsequently lyse, the mainstay of therapy for the past 25 years has been antithrombotic therapy aimed at coronary thrombosis. There have been numerous advances in the treatment of acute coronary syndrome with antiplatelet, antithrombotic, and fibrinolytic agents that have significantly reduced morbidity and mortality. The role of various pharmaceutical agents in the different phases of acute coronary syndrome is a complex and ever changing field.7.
Duvall
W L
WL
Zena and Michael A. Weiner Cardiovascular Institute, Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Box 1030, One Gustave L Levy Place, New York, NY 10029, USA. william.duvall@msnyuhealth.org
D000818:Animals; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000378:metabolism; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013925:Thromboplastin / Q000378:metabolism; D013927:Thrombosis / Q000628:therapy*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D013925:Thromboplastin